News in Brief

Piramal buys GI OTC brand, Shreya wins manufacturing contract

By Staff Reporter

- Last updated on GMT

GettyImages/magicmine
GettyImages/magicmine

Related tags: Marketing

Shreya Lifesciences will continue manufacturing Digeplex after selling the gastro-intestinal (GI) drug to fellow Indian drugmaker Piramal Enterprises.

Piramal announced today it has acquired the OTC Digeplex and associated brands from Shreya Lifesciences in order to complement its branded GI business within India.

Kedar Rajadnye, COO of Piramal’s Consumer Products Division, told in-Pharmatechnologist the firm has only acquired the trademark and commercialisation rights, and not the site where the product is made.

“Piramal Enterprises will continue to use Shreya as a contract manufacturer for the product going forwards,”​ he said. “The CQA team from Piramal Enterprises has audited the Shreya Site and found it to meet our standards.”

Financial details regarding the sale and the manufacturing contract have not been divulged.

Shreya has two manufacturing facilities, both in India. Its Aurangabad plant has capacity for injectables and oral solid dosages, while the Roorkes plant offers oral solids, oral liquids, lozenges and dry powder injectables.

Related news

Follow us

Products

View more

Webinars